GoodRx (NASDAQ:GDRX) Major Shareholder Francisco Partners Iv, L.P. Sells 143,594 Shares of Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 143,594 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $3.46, for a total transaction of $496,835.24. Following the transaction, the insider directly owned 706,649 shares of the company’s stock, valued at approximately $2,445,005.54. This trade represents a 16.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50.
• On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The shares were sold at an average price of $3.44, for a total transaction of $437,819.12.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total transaction of $1,666,071.75.

GoodRx Stock Performance

GDRX opened at $3.65 on Thursday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. The business’s 50 day moving average is $3.18 and its 200-day moving average is $2.66. The stock has a market cap of $1.25 billion, a PE ratio of 91.27, a price-to-earnings-growth ratio of 1.73 and a beta of 1.60. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The business had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. During the same period in the prior year, the company posted $0.09 EPS. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. On average, analysts predict that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GDRX. Vanguard Group Inc. lifted its position in GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after buying an additional 624,182 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of GoodRx by 4.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after acquiring an additional 184,734 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of GoodRx by 1.5% during the 1st quarter. Renaissance Technologies LLC now owns 3,259,738 shares of the company’s stock valued at $6,389,000 after acquiring an additional 48,800 shares in the last quarter. LSV Asset Management increased its stake in shares of GoodRx by 20.0% in the fourth quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock worth $7,658,000 after acquiring an additional 471,319 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of GoodRx by 6.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company’s stock worth $7,183,000 after acquiring an additional 152,934 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wall Street Zen raised GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Wells Fargo & Company upped their price objective on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Leerink Partners set a $5.00 target price on GoodRx in a report on Thursday, August 6th. UBS Group upped their price target on GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $4.00 price objective on shares of GoodRx in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, GoodRx has an average rating of “Hold” and an average target price of $4.23.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.